Notes
See also Reactions 1477 p2; 803095471
Reference
EMA. European Medicines Agency recommends changes in use of leukaemia medicine Iclusig (ponatinib) in order to minimise risk of blood clots. Internet Document : [3 pages], 22 Nov 2013. Available from: URL: http://www.ema.europa.eu
Rights and permissions
About this article
Cite this article
CHMP recommends restricting use of ponatinib. Reactions Weekly 1481, 4 (2013). https://doi.org/10.1007/s40278-013-7557-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-013-7557-x